Chapter 4: Blood pressure management in CKD ND patients with diabetes mellitus

Kidney International Supplements

Volumn 2, Issue 5, 2012, Pages 363-369

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85098492501     PISSN: 21571724     EISSN: 21571716     Source Type: Journal    
DOI: 10.1038/kisup.2012.54     Document Type: Article

References (108)

1. National Kidney Foundation, K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 43 (2004), S1–S290.
2. National Kidney Foundation, K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39 (2002), S1–S266.
3. Chobanian, A.V., Bakris, G.L., Black, H.R., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003), 1206–1252.
4. Lewington, S., Clarke, R., Qizilbash, N., et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 (2002), 1903–1913.
5. Lewis, J.B., Blood pressure control in chronic kidney disease: is less really more?. J Am Soc Nephrol 21 (2010), 1086–1092.
6. National Kidney Foundation, KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 49 (2007), S1–S179.
7. Mehdi, U.F., Adams-Huet, B., Raskin, P., et al. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 20 (2009), 2641–2650.
8. Bianchi, S., Bigazzi, R., Campese, V.M., Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 70 (2006), 2116–2123.
9. Klag, M.J., Whelton, P.K., Randall, B.L., et al. Blood pressure and end-stage renal disease in men. N Engl J Med 334 (1996), 13–18.
10. SHEP Cooperative Research Group, Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 265 (1991), 3255–3264.
11. Weiner, D.E., Tighiouart, H., Levey, A.S., et al. Lowest systolic blood pressure is associated with stroke in stages 3 to 4 chronic kidney disease. J Am Soc Nephrol 18 (2007), 960–966.
12. Cushman, W.C., Evans, G.W., Byington, R.P., et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362 (2010), 1575–1585.
13. Makino, H., Haneda, M., Babazono, T., et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 30 (2007), 1577–1578.
14. Parving, H.H., Lehnert, H., Brochner-Mortensen, J., et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 (2001), 870–878.
15. Brenner, B.M., Cooper, M.E., de Zeeuw, D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001), 861–869.
16. Estacio, R.O., Jeffers, B.W., Gifford, N., et al. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 23:Suppl 2 (2000), B54–B64.
17. Lewis, E.J., Hunsicker, L.G., Clarke, W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001), 851–860.
18. Yusuf, S., Sleight, P., Pogue, J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The HeartOutcomes Prevention Evaluation Study Investigators. N Engl J Med 342 (2000), 145–153.
19. Caramori, M.L., Fioretto, P., Mauer, M., Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions. Diabetes 52 (2003), 1036–1040.
20. Kramer, H.J., Nguyen, Q.D., Curhan, G., Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 289 (2003), 3273–3277.
21. MacIsaac, R.J., Panagiotopoulos, S., McNeil, K.J., et al. Is nonalbuminuric renal insufficiency in type 2 diabetes related to an increase in intrarenal vascular disease?. Diabetes Care 29 (2006), 1560–1566.
22. Perkins, B.A., Ficociello, L.H., Roshan, B., et al. In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int 77 (2010), 57–64.
23. Law, M.R., Morris, J.K., Wald, N.J., Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ, 338, 2009, b1665.
24. Czernichow, S., Zanchetti, A., Turnbull, F., et al. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens 29 (2011), 4–16.
25. O'Seaghdha, C.M., Perkovic, V., Lam, T.H., et al. Blood pressure is a major risk factor for renal death: an analysis of 560 352 participants from the Asia-Pacific region. Hypertension 54 (2009), 509–515.
26. Stamler, J., Vaccaro, O., Neaton, J.D., et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16 (1993), 434–444.
27. White, S.L., Chadban, S.J., Jan, S., et al. How can we achieve global equity in provision of renal replacement therapy?. Bull World Health Organ 86 (2008), 229–237.
28. Adler, A.I., Stevens, R.J., Manley, S.E., et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63 (2003), 225–232.
29. Ritz, E., Dikow, R., Hypertension and antihypertensive treatment of diabetic nephropathy. Nat Clin Pract Nephrol 2 (2006), 562–567.
30. Janka, H.U., Warram, J.H., Rand, L.I., et al. Risk factors for progression of background retinopathy in long-standing IDDM. Diabetes 38 (1989), 460–464.
31. Klein, R., Klein, B.E., Moss, S.E., et al. Is blood pressure a predictor of the incidence or progression of diabetic retinopathy?. Arch Intern Med 149 (1989), 2427–2432.
32. Knowler, W.C., Bennett, P.H., Ballintine, E.J., Increased incidence of retinopathy in diabetics with elevated blood pressure. A six-year follow-up study in Pima Indians. N Engl J Med 302 (1980), 645–650.
33. Teuscher, A., Schnell, H., Wilson, P.W., Incidence of diabetic retinopathy and relationship to baseline plasma glucose and blood pressure. Diabetes Care 11 (1988), 246–251.
34. Gaede, P., Lund-Andersen, H., Parving, H.H., et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358 (2008), 580–591.
35. Gaede, P., Tarnow, L., Vedel, P., et al. Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant 19 (2004), 2784–2788.
36. Gaede, P., Vedel, P., Larsen, N., et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 (2003), 383–393.
37. An, J.H., Cho, Y.M., Yu, H.G., et al. The clinical characteristics of normoalbuminuric renal insufficiency in Korean type 2 diabetic patients: a possible early stage renal complication. J Korean Med Sci 24:Suppl (2009), S75–S81.
38. Bruno, G., Merletti, F., Bargero, G., et al. Estimated glomerular filtration rate, albuminuria and mortality in type 2 diabetes: the Casale Monferrato study. Diabetologia 50 (2007), 941–948.
39. Ito, H., Takeuchi, Y., Ishida, H., et al. High frequencies of diabetic micro- and macroangiopathies in patients with type 2 diabetes mellitus with decreased estimated glomerular filtration rate and normoalbuminuria. Nephrol Dial Transplant 25 (2010), 1161–1167.
40. MacIsaac, R.J., Tsalamandris, C., Panagiotopoulos, S., et al. Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care 27 (2004), 195–200.
41. Thomas, M.C., Macisaac, R.J., Jerums, G., et al. Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (national evaluation of the frequency of renal impairment cO-existing with NIDDM [NEFRON] 11). Diabetes Care 32 (2009), 1497–1502.
42. Yokoyama, H., Sone, H., Oishi, M., et al. Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan Diabetes Clinical Data Management study (JDDM15). Nephrol Dial Transplant 24 (2009), 1212–1219.
43. Molitch, M.E., Steffes, M., Sun, W., et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care 33 (2010), 1536–1543.
44. UK Prospective Diabetes Study Group, Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 317 (1998), 703–713.
45. Hansson, L., Zanchetti, A., Carruthers, S.G., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351 (1998), 1755–1762.
46. Schrier, R.W., Estacio, R.O., Mehler, P.S., et al. Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial. Nat Clin Pract Nephrol 3 (2007), 428–438.
47. Estacio, R.O., Jeffers, B.W., Hiatt, W.R., et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338 (1998), 645–652.
48. Schrier, R.W., Estacio, R.O., Esler, A., et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 61 (2002), 1086–1097.
49. Chew, E.Y., Ambrosius, W.T., Davis, M.D., et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 363 (2010), 233–244.
50. Perry, H.M. Jr, Miller, J.P., Fornoff, J.R., et al. Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 25 (1995), 587–594.
51. Tozawa, M., Iseki, K., Iseki, C., et al. Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension 41 (2003), 1341–1345.
52. Orchard, T.J., Forrest, K.Y., Kuller, L.H., et al. Lipid and blood pressure treatment goals for type 1 diabetes: 10-year incidence data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 24 (2001), 1053–1059.
53. Berl, T., Hunsicker, L.G., Lewis, J.B., et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 16 (2005), 2170–2179.
54. Adler, A.I., Stratton, I.M., Neil, H.A., et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321 (2000), 412–419.
55. Pepine, C.J., Handberg, E.M., Cooper-DeHoff, R.M., et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease.The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 290 (2003), 2805–2816.
56. Cooper-DeHoff, R.M., Gong, Y., Handberg, E.M., et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 304 (2010), 61–68.
57. Patel, A., MacMahon, S., Chalmers, J., et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370 (2007), 829–840.
58. de Galan, B.E., Perkovic, V., Ninomiya, T., et al. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 20 (2009), 883–892.
59. Heerspink, H.J., Ninomiya, T., Perkovic, V., et al. Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. Eur Heart J 31 (2010), 2888–2896.
60. Arauz-Pacheco, C., Parrott, M.A., Raskin, P., The treatment of hypertension in adult patients with diabetes. Diabetes Care 25 (2002), 134–147.
61. European Society of Hypertension-European Society of Cardiology Guidelines Committee, 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21 (2003), 1011–1053.
62. Australian Heart Foundation, Guide to Management of Hypertension, 2008.
63. Levin, A., Hemmelgarn, B., Culleton, B., et al. Guidelines for the management of chronic kidney disease. CMAJ 179 (2008), 1154–1162.
64. Mancia, G., De Backer, G., Dominiczak, A., et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 28 (2007), 1462–1536.
65. Joint British Societies 2 Working Party, JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart 91:Suppl 5 (2005), v1–v52.
66. World Health Organization-International Society of Hypertension (WHO-ISH) Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension, Guidelines Subcommittee. J Hypertens 17 (1999), 151–183.
67. JNC, V.I., The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 157 (1997), 2413–2446.
68. Whitworth, J.A., 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 21 (2003), 1983–1992.
69. Williams, B., Poulter, N.R., Brown, M.J., et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 18 (2004), 139–185.
70. Arauz-Pacheco, C., Parrott, M.A., Raskin, P., Treatment of hypertension in adults with diabetes. Diabetes Care 26:Suppl 1 (2003), S80–S82.
71. American Diabetes Association, Standards of medical care in diabetes–2010. Diabetes Care 33:Suppl 1 (2010), S11–S61.
72. Buse, J.B., Ginsberg, H.N., Bakris, G.L., et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 115 (2007), 114–126.
73. Staessen, J.A., Fagard, R., Thijs, L., et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension.The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 350 (1997), 757–764.
74. Nishimura, R., LaPorte, R.E., Dorman, J.S., et al. Mortality trends in type 1 diabetes. The Allegheny County (Pennsylvania) Registry 1965–1999. Diabetes Care 24 (2001), 823–827.
75. Ibsen, H., Olsen, M.H., Wachtell, K., et al. Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy?The LIFE study. Diabetes Care 29 (2006), 595–600.
76. Ruggenenti, P., Fassi, A., Ilieva, A.P., et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351 (2004), 1941–1951.
77. Ruggenenti, P., Perna, A., Ganeva, M., et al. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. J Am Soc Nephrol 17 (2006), 3472–3481.
78. Gaede, P., Vedel, P., Parving, H.H., et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 353 (1999), 617–622.
79. Bakris, G.L., Weir, M.R., Shanifar, S., et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 163 (2003), 1555–1565.
80. Bakris, G.L., Williams, M., Dworkin, L., et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach.National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 36 (2000), 646–661.
81. Dinneen, S.F., Gerstein, H.C., The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 157 (1997), 1413–1418.
82. Gerstein, H.C., Mann, J.F., Yi, Q., et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286 (2001), 421–426.
83. Ninomiya, T., Perkovic, V., de Galan, B.E., et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 20 (2009), 1813–1821.
84. Atkins, R.C., Briganti, E.M., Lewis, J.B., et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 45 (2005), 281–287.
85. de Zeeuw, D., Remuzzi, G., Parving, H.H., et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 65 (2004), 2309–2320.
86. de Zeeuw, D., Remuzzi, G., Parving, H.H., et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110 (2004), 921–927.
87. Agha, A., Amer, W., Anwar, E., et al. Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: A randomized controlled trial. Saudi J Kidney Dis Transpl 20 (2009), 429–435.
88. ACE Inhibitors in Diabetic Nephropathy Trialist Group, Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors?. A meta-analysis of individual patient data. Ann Intern Med 134 (2001), 370–379.
89. Marre, M., Lievre, M., Chatellier, G., et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ, 328, 2004, 495.
90. Ravid, M., Lang, R., Rachmani, R., et al. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med 156 (1996), 286–289.
91. Ravid, M., Savin, H., Jutrin, I., et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 118 (1993), 577–581.
92. Trevisan, R., Tiengo, A., Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients.North-East Italy Microalbuminuria Study Group. Am J Hypertens 8 (1995), 876–883.
93. National Kidney Foundation, KDOQI clinical practice guideline for diabetes and chronic kidney disease: 2012 update. Am J Kidney Dis 60 (2012), 850–886.
94. Lewis, E.J., Hunsicker, L.G., Bain, R.P., et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329 (1993), 1456–1462.
95. Kasiske, B.L., Kalil, R.S., Ma, J.Z., et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 118 (1993), 129–138.
96. Braunwald, E., Domanski, M.J., Fowler, S.E., et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 351 (2004), 2058–2068.
97. Dagenais, G.R., Pogue, J., Fox, K., et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 368 (2006), 581–588.
98. Dahlof, B., Devereux, R.B., Kjeldsen, S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002), 995–1003.
99. Fox, K.M., Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362 (2003), 782–788.
100. PROGRESS Collaborative Group, Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358 (2001), 1033–1041.
101. Yusuf, S., Teo, K., Anderson, C., et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 372 (2008), 1174–1183.
102. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators, Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 355 (2000), 253–259.
103. Lindholm, L.H., Ibsen, H., Dahlof, B., et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002), 1004–1010.
104. Whelton, P.K., Barzilay, J., Cushman, W.C., et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 165 (2005), 1401–1409.
105. Strippoli, G.F., Craig, M., Deeks, J.J., et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ, 329, 2004, 828.
106. Mann, J.F., Schmieder, R.E., McQueen, M., et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372 (2008), 547–553.
107. Yusuf, S., Teo, K.K., Pogue, J., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 (2008), 1547–1559.
108. Chrysostomou, A., Pedagogos, E., MacGregor, L., et al. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 1 (2006), 256–262.